- Home
- FFIN vs TNGX Comparison
FFIN vs TNGX Comparison
Compare FFIN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFIN | TNGX |
|---|---|---|
| Founded | 1890 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.5B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FFIN | TNGX |
|---|---|---|
| Price | $34.83 | $27.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $36.50 | $21.78 |
| AVG Volume (30 Days) | 742.5K | ★ 2.0M |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | 13.46 | ★ 26.89 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $6.61 | N/A |
| P/E Ratio | $34.26 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $28.12 | $6.25 |
| 52 Week High | $38.12 | $34.39 |
Technical Indicators
Market Signals| Indicator | FFIN | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 47.03 |
| Support Level | $33.92 | $19.74 |
| Resistance Level | $35.00 | $28.41 |
| Average True Range (ATR) | 0.57 | 1.65 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 46.30 | 39.23 |
Price Performance
Historical ComparisonAbout FFIN First Financial Bankshares Inc.
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.